To be Published in the International Journal of Cardiology SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life changing critical illness, announced today the publication of results from its Phase 2 trial of FDY-5301 for the […]

Treatment well tolerated, with encouraging signs to support pivotal trial Results presented at American Heart Association Scientific Sessions 2019 SEATTLE, Nov. 19, 2019 /PRNewswire/ — Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of small molecules for critical care medicine, today announced top-line results from its Phase 2 trial of FDY-5301 for […]